Verily Life Sciences LLC

Joshua Simon Klein

Jerrod Joseph Schwartz

Alberto Clemente Vitari

Andrew Homyk

Jason Donald Thompson

Mark Audeh

Marija Pavlovic

Vikram Singh Bajaj

Victor Marcel Acosta

Stephen Morton

James Michael Higbie

Nathan Higginson-Scott

Nathan Pierce

Anthony M Giannetti

Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting probes associated with circulating cells of the tumor that travel to subsurface vasculature of the body. The probe enters a tumor and associates with cells of the tumor before the cells metastasize. A wearable body-mountable device can be worn for a protracted period of time to detect the probe associated with circulating tumor cells in the vasculature at low concentrations and/or at low rates. A body-mounted device could detect the presence of such released, tumor-cell-associated probes to determine a presence or status of a tumor in the body.

Method of cell tagging for cancer detection

A method for profiling extracellular vesicles (EV) is provided. The method includes: (a) incubating isolated EV from one or more sources with a phage display library under conditions suitable for forming EV-bound phage, wherein the phage display library comprises one or more types of phage, each type of phage having a displayed proteinaceous display binding moieties capable of recognizing one or more epitopes on the surface of the EV, wherein each type of phage comprises nucleic acids encoding the displayed proteinaceous display binding moieties, and wherein the displayed proteinaceous display binding moieties of each type of phage is different; (b) isolating the EV-bound phage; (c) extracting the nucleic acids from the EV-bound phage; (d) amplifying the extracted nucleic acids; (e) sequencing the amplified nucleic acids to identify specific nucleic acid sequences associated with each type of phage from the library that are enriched from the isolated EV; and (f) comparing the specific nucleic acid sequences (output) with nucleic acid sequences from the phage display library (input) and nucleic acid sequences from a control to identify sequences that can distinguish between EV from the one or more sources.

Methods for profiling extracellular vesicles from combinatorial phage display libraries

Body-mountable devices are provided to detect the presence or status of an analyte in subsurface vasculature of a body by detecting fluorescent reporters that are bound to instances of the analyte in the subsurface vasculature. Such devices further operate to exert an attractive magnetic force on magnetic nanoparticle-containing probes that are configured to bind to the analyte, thus concentrating the analyte proximate the devices by magnetically exerting attractive forces on such probes that are bound to instances of the analyte. The analyte can be an extracellular vesicle that is characteristic of a cancer, and a body-mountable device as described herein could be used to detect such extracellular vesicles in a portion of subsurface vasculature such that a presence or status of a tumor could be determined based on an amount, presence, or other detected property of the extracellular vesicle.

Magnetic probes for in vivo capture and detection of extracellular vesicles

Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting one or more properties of a probe located in subsurface vasculature of the body. A wearable body-mountable device can be worn for a protracted period of time to detect a probe in the vasculature at low concentrations and/or at low rates. A body-mountable device can detect properties of the probe that are indicative of whether the probe has interacted with a tumor of the body and determine the presence or status of a tumor in the body based on such detected properties. Additionally or alternatively, the probe could be introduced into the body as a probe aggregate and released from if the probe aggregate is absorbed by a tumor. The presence of released probes could be detected to determine a presence or status of a tumor in the body.

Enhanced cancer detection through probe modification

A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Shielded targeting agents, methods, and in vivo diagnostic system

A device and system for detecting an antigen present in a sample is provided. The system includes a cartridge and a reader device. The cartridge includes a solid support having an addressable array of at least one type of antibody that is specific for a target antigen and forms a complex in the presence of the target antigen, a substrate having a mounting surface for the solid support, Protein M for competitively displacing the target antigen from the complex, and a housing for protecting the substrate. The reader device is configured to detect the antigen in a liquid sample via interaction with the cartridge.

Biosensor for in vitro detection system and method of use

A wearable device mounted on a living body can detect an analyte response signal transmitted from tissue in the living body. The tissue contains at particles conjugated to at least one complex of (i) an antibody labeled with a fluorophore, the labeled antibody having a target analyte binding site; and (ii) protein M labeled with a quencher that is complimentary to the fluorophore of the labeled antibody, wherein the labeled protein M competes with the target analytes for the target analyte binding site on the labeled antibody; wherein the fluorophore and quencher are spectrally matched such that there is a detectable change in the fluorescent signal. The analyte response signal is related to interaction of the target analytes with the complexes. A processor can determine a presence or absence of the analytes based on the analyte response signal.

Growing community of inventors

Mountain View, CA, United States of America

Joshua Simon Klein